Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2019

01-12-2019 | ASO Author Reflections

ASO Author Reflections: Venous Thromboembolism after CRS/HIPEC

Authors: Joel M. Baumgartner, MD, MAS, Sohini Khan, MD

Published in: Annals of Surgical Oncology | Special Issue 3/2019

Login to get access

Excerpt

Stasis, hypercoagulability, and endothelial injury are the classic risk factors associated with venous thromboembolism (VTE) and are arguably all present after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Indeed, malignancy and extensive cancer surgery are known to increase the VTE risk compared with noncancer surgery.1 However, the incidence of VTE after CRS/HIPEC has not been well defined, nor have unique risk factors for VTE in this population been identified. Furthermore, although pharmacothromboprophylaxis guidelines have been shown to be effective in preventing VTE after major cancer surgery,2 pharmacoprophylaxis strategies for VTE have not been investigated after CRS/HIPEC. Therefore, we wanted to better define the incidence, risk factors, and prevention strategies of VTE in these patients at our institution. …
Literature
1.
Osborne NH, Wakefield TW, Henke PK. Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol. 2008; 15(12):3567–78.CrossRef
2.
Serrano PE, et al. Venous thromboembolic events following major pelvic and abdominal surgeries for cancer: a prospective cohort study. Ann Surg Oncol. 2018;25(11):3214–21.CrossRef
3.
Khan S, Kelly KJ, Veerapong J, Lowy AM, Baumgartner JM. Incidence, risk factors, and prevention strategies for venous thromboembolism after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26:2276–84.CrossRef
4.
Lanuke K, Mack LA, Temple WJ. A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Can J Surg. 2009;52(1):18–22.PubMedPubMedCentral
5.
Rottenstreich A, et al. Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2017;116(7):914–20.CrossRef
Metadata
Title
ASO Author Reflections: Venous Thromboembolism after CRS/HIPEC
Authors
Joel M. Baumgartner, MD, MAS
Sohini Khan, MD
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07884-w

Other articles of this Special Issue 3/2019

Annals of Surgical Oncology 3/2019 Go to the issue

ASO Author Reflections

ASO Author Reflections: Better Understanding of What We Have Learned from Cancer Care Quality Metrics

ASO Author Reflections

ASO Author Reflections: Recurrent Retroperitoneal Well-Differentiated Liposarcoma

ASO Author Reflections

ASO Author Reflections: Can Minimally Invasive Techniques Improve Quality of Life following Pancreatic Resection?

ASO Author Reflections

ASO Author Reflections: The Changing Landscape for Industry Support to Surgical Oncologists

ASO Author Reflections

ASO Author Reflections: Can the Association Between Obesity and Colorectal Cancer Be Explained by an Unfavorable Tumor Immune Microenvironment?

ASO Author Reflections

ASO Author Reflections: Multimodal Strategy Controls Pain and Reduces Opioid Prescription in Outpatient Breast Surgery